Thiogenesis Therapeutics Announces Consulting and Investor Relations Agreement with Bull Markets Media GmbH
San Diego, California – February 20, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”), a clinical-stage biotechnology company specializing in the development of disulfides that stimulate the production of essential intracellular antioxidants and other therapeutic compounds, has recently announced a significant move in its investor relations strategy. Effective February 15, 2025, the Company entered into a consulting and investor relations agreement (the “Agreement”) with Bull Markets Media GmbH (the “Consultant”), a well-known digital stock market news portal based in Germany.
Services Provided by Bull Markets Media GmbH
Under the terms of the Agreement, the Consultant will provide Thiogenesis with a range of services aimed at broadening the Company’s European shareholder base and expanding its contact network within Europe. Specifically, the Consultant will:
- Analyze and assess potential opportunities to increase Thiogenesis’ presence within the European investment community;
- Collaborate with the Company to develop and execute targeted investor outreach strategies;
- Provide regular market analysis and investor sentiment reports;
- Assist in arranging and preparing for investor meetings and conferences;
- Support the Company’s communications efforts, including translations and distribution of press releases and other materials.
Impact on Thiogenesis and its Stakeholders
This strategic partnership with Bull Markets Media GmbH represents a significant step forward in Thiogenesis’ efforts to expand its reach and engage with European investors. By tapping into the Consultant’s expertise and extensive network, the Company aims to strengthen its investor relations and further its mission to develop innovative therapeutic solutions based on its proprietary disulfide technology.
Global Implications
Beyond the immediate benefits to Thiogenesis and its shareholders, this agreement also underscores the growing importance of European investment communities in the biotechnology sector. As global markets continue to evolve and interconnect, companies like Thiogenesis are increasingly recognizing the value of a diverse and international investor base. This trend is likely to continue, as biotech firms seek to capitalize on the unique strengths and opportunities presented by various global markets.
Conclusion
Thiogenesis Therapeutics’ announcement of its consulting and investor relations agreement with Bull Markets Media GmbH represents a strategic move to expand its presence in Europe and broaden its investor base. This partnership is expected to provide valuable insights and support in navigating the European investment landscape. The agreement also speaks to the growing importance of international investment communities in the biotechnology sector, a trend that is likely to continue shaping the industry in the years to come.
As a curious human, I’m excited to see how this partnership unfolds and the potential impact it will have on Thiogenesis and the broader biotech industry. Stay tuned for more updates on this developing story!
